Lung cancer is the most common type of cancer in Scotland with around 5,500 cases diagnosed each year, according to Scottish Government figures.
Most people diagnosed with lung cancer are 60 years old or older, with smokers also more likely to suffer. The illness can also be caused by second-hand smoke as well as radiation and substances such as asbestos, chromium and nickel compounds, reports the Mirror. However, younger people and non-smokers may also be diagnosed.
However, there are other, lesser known signs that should also be looked out for - such as pain or weakness in your shoulder. Clubbing of the fingers is also linked to lung cancer. This is where the tips of the fingers become swollen due to lack of oxygen. Cancerous cells can also release large quantities of hormones that can cause symptoms experienced in other parts of the body. It means that some may experience extreme fatigue and weight loss.
However, it is important to note that experiencing any symptoms listed above does not necessarily mean you have lung cancer and can instead be linked to many other, less serious health conditions.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
New trial shows promise of combination neoadjuvant immunotherapy for lung cancerPatients with stage 1–3 non-small cell lung cancer (NSCLC) given a combination immunotherapy prior to surgery (neoadjuvant) had a better major pathological response (10% or less residual cancer) when the cancer was removed than those who took a single immunotherapy agent alone, according to results of a novel multicenter phase 2 NeoCOAST platform trial that included two investigators from the Johns Hopkins Kimmel Cancer Center and its Bloomberg-Kimmel Institute for Cancer Immunotherapy.
Source: NewsMedical - 🏆 19. / 71 Read more »
Combination immunotherapy outperforms durvalumab monotherapy in neoadjuvant NSCLCCombination immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant (pre-surgical) setting for early-stage non-small-cell lung cancer (NSCLC), according to researchers at The University of Texas MD Anderson Cancer Center.
Source: NewsMedical - 🏆 19. / 71 Read more »
New trial shows promise of combination neoadjuvant immunotherapy for lung cancerPatients with stage 1–3 non-small cell lung cancer (NSCLC) given a combination immunotherapy prior to surgery (neoadjuvant) had a better major pathological response (10% or less residual cancer) when the cancer was removed than those who took a single immunotherapy agent alone, according to results of a novel multicenter phase 2 NeoCOAST platform trial that included two investigators from the Johns Hopkins Kimmel Cancer Center and its Bloomberg-Kimmel Institute for Cancer Immunotherapy.
Source: NewsMedical - 🏆 19. / 71 Read more »